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vealed, a decrease in peak ground reaction forces of the ex-
perimental leg related to the course of OA (p<0.05). This was
supported by the structural end point measurements. Cartilage
integrity was damaged as reﬂected by an increased macroscopic
( +2.2) and histological score ( +2.0), and by a decreased
proteoglycan content (-20%; all p<0.05). Chondrocyte activity
demonstrated an increase in proteoglycan synthesis rate (+73%)
and release (+64%; both p<0.05). Furthermore, synovial inﬂam-
mation was present macroscopically ( +3.5), and histologically
( +2.0; both p<0.05). This was corroborated by increased syn-
ovial ﬂuid whit blood cell count (WBCC  +1.5) and NO levels
(+30%) increasing during the course of OA.
In the treatment group glycine uptake could be demonstrated:
glycine was found in sufﬁcient amounts in serum and synovial
ﬂuid over time (all time points p<0.05). However, as a result
of treatment no changes in cartilage parameters, osteophyte
formation, and gait were observed. Also, no changes in end stage
inﬂammation and synovial ﬂuid MMP activity were observed.
However, synovial ﬂuid WBCC, and NO production were slightly,
temporarily, but statistically signiﬁcantly (p<0.05) decreased in
the glycine treatment group compared to the placebo group
during the course of OA development.
Conclusions: Glycine, as a potential anti-inﬂammatory agent,
is absorbed by the gastro intestinal tract and reaches serum
and synovial ﬂuid, leading to minor temporary changes in joint
inﬂammation which are not reﬂected by structural and clinical
relevant changes during development of experimentally induced
osteoarthritis in de ACLT-Mx model.
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Purpose: Although topical NSAIDs have been used for many
years, additional supporting evidence of their value is needed.
This study was conducted to determine the efﬁcacy and safety
of topical diclofenac sodium gel 1% (DSG) in knee osteoarthritis
(KOA).
Methods: Patients in this double-blind, randomized, parallel-
group, multicenter 12-week trial had a history of primary KOA
(meeting American College of Rheumatology [ACR] criteria),
diagnosed at least 6 months prior to study entry and symptomatic
in only 1 knee. Patients were randomized to DSG (n=254) or
vehicle (n=238), applied as 4 g to the signal knee 4 times daily.
After a 7-day washout from previous pain medication, baseline
pain on movement was at least 50 mm on a 100-mm visual
analog scale (VAS), and the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) pain subscale was at
least 9 (out of 20; Likert scale v 3.1). Acetaminophen up to 4
g per day was permitted as rescue medication throughout the
study. Primary efﬁcacy variables at Week 12 included WOMAC
pain subscale (scale = 0 to 20), WOMAC function subscale
(scale = 0 to 68), and global rating of disease (100 mm VAS).
Secondary outcome variables included efﬁcacy at other time
points of the study, success rates based on the Osteoarthritis
Research Society International (OARSI) response criteria, and
use of rescue medication. Safety was assessed at all time points.
Results: Disposition: 77% completed the study. Demographics:
women 2:1 men; 75% white; mean age 60 years (2/3 between
50 and 70); mean pain on movement 71 mm by VAS; mean
WOMAC pain 12. Prior to unblinding, the protocol was amended
to exclude from the efﬁcacy analysis patients with signiﬁcant pain
at baseline in the contralateral knee and/or a decrease in pain on
Table 1. WOMAC pain, WOMAC physical function, and global rating of disease
at Week 12
DSG (n=127) Vehicle (n=119) P-value
WOMAC pain
Mean 5.62 7.38 0.023
Mean  from baseline 5.85 4.68
WOMAC physical function
Mean 19.67 25.72 0.003
Mean  from baseline 17.50 11.80
Patient global
Mean 31.6 41.5 0.018
Mean  from baseline 30.0 22.4
DSG = diclofenac sodium gel 1%; WOMAC = Western Ontario and McMaster
Universities Osteoarthritis Index.
movement over the washout from the screening to the baseline
visit. Table 1 shows the results in the primary efﬁcacy variables
at Week 12. On all important secondary endpoints, patients on
active treatment had a signiﬁcantly better outcome than patients
randomized to vehicle. Table 2 shows response rates based on
the OARSI success criteria.
Table 2. OARSI response, WOMAC pain index normalized to 100-pt scale
OARSI response rate, n (%) DSG, (n=127) Vehicle, (n=119) P-value
Week 1 87 (68.5) 59 (49.6) 0.005
Week 4 94 (74.0) 72 (60.5) 0.043
Week 8 95 (74.8) 70 (58.8) 0.013
Week 12 94 (74.0) 70 (58.8) 0.024
DSG = diclofenac sodium gel 1%; WOMAC = Western Ontario and McMaster
Universities Osteoarthritis index; OARSI = Osteoarthritis Research Society In-
ternational.
The mean number of weeks with no rescue medication use was
signiﬁcantly greater in the DSG group (4.7 weeks) compared
with the vehicle group (3.1 weeks, P=.004).
Adverse events overall were slightly more frequent in the DSG
group than in the vehicle group (60.2% vs 53.8%) with most AEs
being mild or moderate in severity. The incidence of mild gas-
trointestinal disorders was low and comparable in both treatment
groups (DSG: 5.9%, vehicle: 5.0%). Incidence of application site
dermatitis was higher in the DSG group: 4.3% compared with
1.7% in the vehicle group. However, discontinuation rates due to
application site conditions were low in both groups (DSG: 2.0%,
vehicle: 0.8%). Rates of discontinuation of treatment due to AEs
overall were slightly higher in the active treatment group (DSG:
5.1%, vehicle: 3.8%).
Conclusions: In a double-blind, controlled trial, topical diclofenac
sodium gel 1% was superior to vehicle in reducing pain, improv-
ing physical function, and patient global rating of disease for
KOA. DSG was well tolerated.
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Purpose: The sequence of AC-100 is derived from a central 23-
amino acid region of MEPE - an extracellular matrix protein and
is one of the more conserved regions of the molecule. AC-100
has shown speciﬁc activity in vivo to promote tissue appropriate
hard tissue deposition in teeth and in bone. Cell culture studies
have shown AC-100 has potent anabolic activity on osteoblast
and odontoblast precursor cells in vitro. Local PGE2 production
